# PNCK

## Overview
PNCK, or pregnancy up-regulated nonubiquitous CaM kinase, is a gene that encodes a serine/threonine kinase belonging to the calcium/calmodulin-dependent protein kinase (CaMK) family. The protein product of PNCK is involved in various cellular processes, including signal transduction pathways that regulate cell proliferation and differentiation. It is particularly noted for its role in the ligand-independent degradation of the epidermal growth factor receptor (EGFR), a process that is independent of calcium and calmodulin, suggesting a unique mechanism of action (Deb2011Pnck). PNCK is expressed in multiple isoforms due to alternative splicing and is primarily active in the cytoplasm and nucleus, where it influences gene expression and cellular responses to external stimuli (Perry2000Cloning; Deb2011Pnck). The protein's interactions with other cellular components, such as the heat shock protein 90 (Hsp90) chaperone complex, further underscore its significance in modulating protein stability and signaling pathways, with implications in cancer biology (Deb2011Pnck; Ding2024Inhibition).

## Structure
The PNCK protein is a serine/threonine kinase belonging to the calcium/calmodulin-dependent protein kinase (CaMK) family. It encodes a 343-amino acid polypeptide with a predicted molecular mass of 38.6 kDa (Perry2000Cloning). The primary structure of PNCK includes a unique 14-amino-acid amino-terminal segment, a 256-amino-acid kinase catalytic domain, a 41-amino-acid regulatory domain, and a 32-amino-acid unique carboxyl-terminal region (Perry2000Cloning). The kinase catalytic domain contains motifs conserved among serine/threonine kinases, which are crucial for its enzymatic activity (Perry2000Cloning).

The secondary and tertiary structures of PNCK are not explicitly detailed in the available context. However, the presence of conserved motifs suggests a typical kinase fold, which includes an ATP-binding site and a substrate-binding site, common features in the tertiary structure of kinases.

PNCK is expressed in multiple isoforms due to alternative splicing, as indicated by the existence of rat homologues expressed as two isoforms, CaMKIβ1 and CaMKIβ2, which are homologous to Pnck clones V1 and U7 (Perry2000Cloning). The protein may undergo post-translational modifications such as phosphorylation, which is typical for kinases, although specific modifications for PNCK are not detailed in the context.

## Function
PNCK (pregnancy up-regulated nonubiquitous CaM kinase) is a serine/threonine kinase involved in several molecular processes within healthy human cells. It is part of the Ca2+/calmodulin-dependent protein kinase family and plays a significant role in signal transduction pathways that regulate cell proliferation and differentiation (Perry2000Cloning). PNCK is known to induce ligand-independent degradation of the epidermal growth factor receptor (EGFR) by potentially disrupting the Hsp90 chaperone complex. This process is independent of calcium and calmodulin, suggesting a unique mechanism of action for PNCK in EGFR regulation (Deb2011Pnck).

In cellular biology, PNCK is implicated in modulating the cell cycle, particularly influencing the transition from the S to G2 phase. This is achieved through the downregulation of the cyclin-dependent kinase inhibitor p21, which is mediated by MAP kinase activity (Deb2011Pnck). PNCK's activity is not solely dependent on its kinase function, as it can still induce EGFR degradation even when its kinase activity is impaired (Deb2011Pnck). The protein is primarily active in the cytoplasm and nucleus, where it influences gene expression and cellular responses to external stimuli (Deb2011Pnck).

## Clinical Significance
PNCK (pregnancy up-regulated nonubiquitous CaM kinase) has been implicated in various cancers due to its altered expression levels. It is significantly overexpressed in several cancer types, including renal cell carcinoma, lung squamous cell carcinoma, and liver hepatocellular carcinoma, with log2 fold changes greater than 5 or 6, suggesting a tumor-specific need for PNCK activity (Essegian2020The). In nasopharyngeal carcinoma (NPC), PNCK is upregulated compared to normal tissues, and its depletion inhibits cell proliferation and induces apoptosis, affecting the PI3K/AKT/mTOR signaling pathway (Xu2019PNCK).

PNCK's expression is associated with lower overall survival in several cancers, including adrenocortical carcinoma, glioblastoma, and kidney renal clear cell carcinoma, highlighting its potential as a prognostic marker (Southekal2021PanCancer). Despite its clinical significance, PNCK is not currently targeted by FDA-approved drugs, although the non-specific CaMK inhibitor KN-93 has shown potential in pre-clinical models to induce cell-cycle arrest and apoptosis (Essegian2020The). These findings suggest that PNCK could be a novel therapeutic target in cancer treatment, warranting further investigation into its role and potential as a drug target.

## Interactions
PNCK, or pregnancy up-regulated nonubiquitous CaM kinase, interacts with several proteins, influencing various cellular processes. One significant interaction is with the heat shock protein 90 (Hsp90) chaperone complex. PNCK is identified as a client protein of Hsp90, and its association with this complex is influenced by culture conditions, such as the presence of serum (Deb2011Pnck). PNCK's interaction with Hsp90 is crucial for the ligand-independent degradation of the epidermal growth factor receptor (EGFR), as it appears to perturb the Hsp90 complex, leading to EGFR degradation (Deb2011Pnck).

PNCK also affects the phosphorylation state of Hsp90, potentially causing global conformational changes that impact the chaperone's function and client protein maturation (Deb2011Pnck). This interaction suggests that PNCK may regulate Hsp90's posttranslational modifications, particularly phosphorylation (Deb2011Pnck).

In the context of cancer, PNCK interacts with the transcriptional repressor ZEB1, influencing its expression and phosphorylation. This interaction promotes ZEB1 nuclear translocation, affecting cytokine production and immune response within the tumor microenvironment (Ding2024Inhibition). These interactions highlight PNCK's role in modulating protein stability and signaling pathways.


## References


[1. (Perry2000Cloning) Heather Perry Gardner, Jayant V. Rajan, Seung I. Ha, Neal G. Copeland, Debra J. Gilbert, Nancy A. Jenkins, Sandra T. Marquis, and Lewis A. Chodosh. Cloning, characterization, and chromosomal localization of pnck, a ca2+/calmodulin-dependent protein kinase. Genomics, 63(2):279–288, January 2000. URL: http://dx.doi.org/10.1006/GENO.1999.6091, doi:10.1006/geno.1999.6091. This article has 48 citations and is from a peer-reviewed journal.](https://doi.org/10.1006/GENO.1999.6091)

[2. (Ding2024Inhibition) Qin Ding, Youliang Weng, Ying Li, Wanzun Lin, Xiaosan Lin, Tingting Lin, Hanxuan Yang, Wenqian Xu, Jianming Wang, Hongmei Ying, and Sufang Qiu. Inhibition of pnck inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer, 12(10):e009893, October 2024. URL: http://dx.doi.org/10.1136/jitc-2024-009893, doi:10.1136/jitc-2024-009893. This article has 0 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jitc-2024-009893)

[3. (Essegian2020The) Derek Essegian, Rimpi Khurana, Vasileios Stathias, and Stephan C. Schürer. The clinical kinase index: a method to prioritize understudied kinases as drug targets for the treatment of cancer. Cell Reports Medicine, 1(7):100128, October 2020. URL: http://dx.doi.org/10.1016/j.xcrm.2020.100128, doi:10.1016/j.xcrm.2020.100128. This article has 58 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.xcrm.2020.100128)

[4. (Deb2011Pnck) Tushar B. Deb, Annie H. Zuo, Youhong Wang, Robert J. Barndt, Amrita K. Cheema, Surojeet Sengupta, Christine M. Coticchia, and Michael D. Johnson. Pnck induces ligand-independent egfr degradation by probable perturbation of the hsp90 chaperone complex. American Journal of Physiology-Cell Physiology, 300(5):C1139–C1154, May 2011. URL: http://dx.doi.org/10.1152/ajpcell.00167.2010, doi:10.1152/ajpcell.00167.2010. This article has 19 citations.](https://doi.org/10.1152/ajpcell.00167.2010)

[5. (Xu2019PNCK) Yuanji Xu, Jiling Wang, Shaoli Cai, Guanghao Chen, Nanyang Xiao, Yajuan Fu, Qi Chen, and Sufang Qiu. Pnck depletion inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cells in vitro and in vivo. Journal of Cancer, 10(27):6925–6932, 2019. URL: http://dx.doi.org/10.7150/jca.33698, doi:10.7150/jca.33698. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.7150/jca.33698)

[6. (Southekal2021PanCancer) Siddesh Southekal, Nitish Kumar Mishra, and Chittibabu Guda. Pan-cancer analysis of human kinome gene expression and promoter dna methylation identifies dark kinase biomarkers in multiple cancers. Cancers, 13(6):1189, March 2021. URL: http://dx.doi.org/10.3390/cancers13061189, doi:10.3390/cancers13061189. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers13061189)